We read with great interest the article titled “Neoadjuvant Therapy for Rectal Cancer Affects Lymph Node Yield and Status Without Clear Implications on Outcome: The Case for Eliminating a Metric and Using Preoperative Staging to Guide Therapy” by Abdel-Misih et al.1 We came across another article on a similar topic,2 but with conflicting conclusions.
In their study, based on the National Cancer Database (NCDB), Abdel-Misih et al concluded that nodal yield in rectal cancer is multifactorial, and that node yield and status were not significant predictors of overall survival (OS). Thus, nodal metric may not be clinically relevant in the era of neoadjuvant therapy. Conversely, the other article2 stated that their study, also based on the NCDB, clearly demonstrated that lymph node yield is associated with OS in stage I–III rectal cancer, independent of neoadjuvant therapy.
In rectal cancer, neoadjuvant therapy combinations are considered the standard of care, with variations in approach depending on the center.3,4 But these 2 different results based on the same database are confusing. Can the authors clarify these 2 contradictory results?
Mesut Tez, MD
Baris Yildiz, MD
Sabri Ozden, MD
Ankara Numune Teaching Hospital, Turkey
Call for Correspondence
JNCCN is committed to providing a forum to enhance collaboration between academic medicine and the community physician. We welcome comments about the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), articles published in the journal, or any other topic relating to cancer prevention, detection, treatment, supportive care, or survivorship.
Letters should be no more than 400 words, with no more than 5 references if included. Please include the full names, degrees, and affiliations of all letter authors and a phone number or e-mail address for contact.
Letters are considered for publication as space allows. NCCN reserves the right not to publish correspondence for any reason it deems appropriate. All letters are subject to editing and/or abridgment.